- Home
- CLLS vs LUCD Comparison
CLLS vs LUCD Comparison
Compare CLLS & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- LUCD
- Stock Information
- Founded
- CLLS 1999
- LUCD 2018
- Country
- CLLS France
- LUCD United States
- Employees
- CLLS N/A
- LUCD N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CLLS Health Care
- LUCD Health Care
- Exchange
- CLLS Nasdaq
- LUCD Nasdaq
- Market Cap
- CLLS 144.4M
- LUCD 135.6M
- IPO Year
- CLLS 2007
- LUCD 2021
- Fundamental
- Price
- CLLS $1.58
- LUCD $1.13
- Analyst Decision
- CLLS Buy
- LUCD Strong Buy
- Analyst Count
- CLLS 3
- LUCD 4
- Target Price
- CLLS $7.00
- LUCD $3.88
- AVG Volume (30 Days)
- CLLS 79.4K
- LUCD 961.7K
- Earning Date
- CLLS 05-27-2025
- LUCD 05-14-2025
- Dividend Yield
- CLLS N/A
- LUCD N/A
- EPS Growth
- CLLS N/A
- LUCD N/A
- EPS
- CLLS N/A
- LUCD N/A
- Revenue
- CLLS $49,217,000.00
- LUCD $4,346,000.00
- Revenue This Year
- CLLS $48.52
- LUCD $107.75
- Revenue Next Year
- CLLS $5.17
- LUCD $231.37
- P/E Ratio
- CLLS N/A
- LUCD N/A
- Revenue Growth
- CLLS 435.38
- LUCD 79.00
- 52 Week Low
- CLLS $1.10
- LUCD $0.63
- 52 Week High
- CLLS $3.32
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- CLLS 60.44
- LUCD 36.90
- Support Level
- CLLS $1.46
- LUCD $1.19
- Resistance Level
- CLLS $1.65
- LUCD $1.24
- Average True Range (ATR)
- CLLS 0.08
- LUCD 0.07
- MACD
- CLLS -0.00
- LUCD -0.01
- Stochastic Oscillator
- CLLS 75.00
- LUCD 4.17
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.